Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial
Richard B. Warren(Manchester Academic Health Science Centre), Jóhann E. Guðjónsson(University of Michigan), Andrzej Kaszuba(Centrum Medyczne iMed24), Bruce Randazzo, Waldemar Placek(University of Warmia and Mazury in Olsztyn), Paul F. Lizzul, Adam Reich(Rzeszów University of Technology), C.E.M. Griffiths(King's College London), Jihao Zhou
Cited by 57
Related Papers
Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways
|Nature Genetics|2009|1.4k
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity
|Nature Genetics|2012|1k
Definition of treatment goals for moderate to severe psoriasis: a European consensus
|Archives of Dermatological Research|2010|892
Assessment of Pruritus Intensity: Prospective Study on Validity and Reliability of the Visual Analogue Scale, Numerical Rating Scale and Verbal Rating Scale in 471 Patients with Chronic Pruritus
|Acta Dermato Venereologica|2012|579
Visual Analogue Scale: Evaluation of the Instrument for the Assessment of Pruritus
|Acta Dermato Venereologica|2012|502